Byrne, B. J., Schoser, B., Kishnani, P. S., Bratkovic, D., Clemens, P. R., Goker-Alpan, O., … Mozaffar, T. (2025). Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02). J Neurol, 272(3), 213. https://doi.org/10.1007/s00415-025-12899-3

Byrne, Barry J., Benedikt Schoser, Priya S. Kishnani, Drago Bratkovic, Paula R. Clemens, Ozlem Goker-Alpan, Xue Ming, et al. “Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).” J Neurol 272, no. 3 (February 17, 2025): 213. https://doi.org/10.1007/s00415-025-12899-3.

Byrne BJ, Schoser B, Kishnani PS, Bratkovic D, Clemens PR, Goker-Alpan O, et al. Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02). J Neurol. 2025 Feb 17;272(3):213.

Byrne, Barry J., et al. “Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).” J Neurol, vol. 272, no. 3, Feb. 2025, p. 213. Pubmed, doi:10.1007/s00415-025-12899-3.

Byrne BJ, Schoser B, Kishnani PS, Bratkovic D, Clemens PR, Goker-Alpan O, Ming X, Roberts M, Vorgerd M, Sivakumar K, van der Ploeg AT, Goldman M, Wright J, Holdbrook F, Jain V, Benjamin ER, Johnson F, Das SS, Wasfi Y, Mozaffar T. Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02). J Neurol. 2025 Feb 17;272(3):213.